Immutep reports no adverse events in Phase I trial of IMP761, a LAG-3 agonist for autoimmune diseases, with more data expected in 2025. Immutep Limited has released promising initial safety data for ...
Initial pharmacological data from placebo-controlled, double-blind Phase I study shows significant T cell suppression and a favourable safety profile at dosing level of 0.9 mg/kg The substantial ...
IMP761 is designed to enhance the “brake” function of LAG-3 on T cells to restore balance to the immune system and address the underlying cause of many autoimmune diseases Safety data from this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results